SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK's licensor Hansoh Pharma announced positive Phase III results for…

GSK plc · 6-K filed Jul 28, 2026 at 13:03 ET

At the news

BULLISHIMPACT 6/10

6-K filed Jul 28, 2026 at 13:03 ET

GSK's licensor Hansoh Pharma announced positive Phase III results for risvutatug rezetecan (Ris-Rez) in relapsed osteosarcoma, meeting the primary endpoint of progression-free survival. This is the second positive Phase III readout for Ris-Rez, following recent pivotal data in small-cell lung cancer, and strengthens the asset's late-stage profile. The news is a positive pipeline catalyst for GSK's oncology program, though Ris-Rez is still in development and not yet generating revenue, limiting near-term financial impact.

  • Hansoh Pharma's ARTEMIS-011 Phase III trial of Ris-Rez met its primary endpoint of progression-free survival in relapsed osteosarcoma.
  • Ris-Rez is the only B7-H3-targeted ADC to deliver positive Phase III outcomes across multiple tumor types (osteosarcoma and SCLC).
  • GSK holds exclusive global rights to develop and commercialize Ris-Rez outside mainland China, Hong Kong, Macau, and Taiwan.
  • Ris-Rez has US FDA Breakthrough Therapy Designation in relapsed or refractory osteosarcoma and relapsed/refractory extensive-stage SCLC.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access